Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Primary Malignant Peripheral Nerve Sheath Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myelomonocytic, Chronic 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5fludarabine 5Whole-Body Irradiation 4Busulfan 4Biopsy 4Specimen Handling 3Injections 3Cytarabine 3venetoclax 2decitabine and cedazuridine drug combination 2Tacrolimus 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporine 2CPX-351 2Azacitidine 2treosulfan 1peginterferon alfa-2b 1olutasidenib 1itacitinib 1canakinumab 1aldesleukin 1X-Rays 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × Vorinostat × 30 days × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡